GlassScriptPhysician profile
Anbar Ahmad
NPI 1861703159
$6,595.92
in general payments reported to CMS, 2019-2025
50 companies · $962 in 2025
The $962 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $416 · 2021: $533 · 2022: $1,439 · 2023: $1,405 · 2024: $1,619 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,976 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,975.93 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,053.13 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $731.83 | 2019-2025 | |
| Novo Nordisk INC | $596.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $365.42 | 2021-2025 | Afrezza |
| Amgen INC. | $363.63 | 2020-2025 | Tepezza, Repatha, Evenity |
| Xeris Pharmaceuticals, INC. | $318.03 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Cequr Corporation | $246.26 | 2022-2025 | Cequr Simplicity |
| Abbvie INC. | $212.39 | 2019-2025 | Synthroid |
| Abbott Laboratories | $201.95 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $196.71 | 2024-2025 | Veozah |
| Insulet Corporation | $173.79 | 2021-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $156.59 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $140.26 | 2023 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $131.01 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $124.98 | 2021-2024 | Unithroid |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $121.53 | 2019-2024 | Tirosint, Licart, Tirosint |
| Corcept Therapeutics | $116.93 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.30 | 2019-2024 | Jardiance |
| Antares Pharma, INC. | $101.35 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Dexcom, INC. | $97.84 | 2021-2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $81.18 | 2022-2024 | Crysvita |
| Neurocrine Biosciences, INC. | $68.68 | 2024-2025 | |
| Radius Health, INC. | $65.99 | 2023-2024 | Tymlos |
| Ascensia Diabetes Care US INC. | $64.65 | 2023-2024 | |
| Currax Pharmaceuticals LLC | $61.53 | 2022-2024 | Contrave, Nexlizet, Nexletol |
| Esperion Therapeutics, INC. | $48.44 | 2021-2024 | Nexletol |
| Medtronic, INC. | $46.62 | 2022-2025 | Minimed 780g |
| Embecta Corp. | $46.11 | 2024 | |
| Echosens North America, INC. | $45.20 | 2024 | Fibroscan |
| Averitas Pharma INC. | $44.75 | 2023-2024 | Qutenza |
| Janssen Pharmaceuticals, INC | $41.76 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.60 | 2022-2023 | Cycloset |
| Vivus LLC | $38.35 | 2022-2023 | Qsymia |
| Globus Medical, INC. | $34.78 | 2025 | Senza |
| Nevro Corp. | $33.19 | 2023 | Senza |
| Lifescan, INC. | $23.31 | 2022 | |
| Verity Pharmaceuticals INC. | $23.13 | 2024 | Tlando |
| Beta Bionics, INC. | $21.27 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Galderma Laboratories, L.P. | $20.50 | 2024 | Dysport |
| Kyowa Kirin, INC. | $20.00 | 2025 | |
| Bigfoot Biomedical INC | $19.76 | 2022 | |
| Amarin Pharma, INC. | $19.37 | 2021 | |
| Pfizer INC. | $18.20 | 2023 | |
| Sequel Med Tech, LLC | $17.82 | 2025 | Twiist |
| Azurity Pharmaceuticals, INC. | $17.63 | 2023 | Adthyza |
| Eusa Pharma (US) LLC | $15.36 | 2022 | |
| Recordati_rare_diseases_inc. | $15.36 | 2022 | |
| Grt US Holding, INC. | $13.86 | 2021 | |
| Merck Sharp & Dohme LLC | $12.98 | 2019 | |
| Medtronic Minimed, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anbar Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.